Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
6.71
-0.14 (-2.04%)
At close: Apr 28, 2026, 4:00 PM EDT
6.70
-0.01 (-0.15%)
After-hours: Apr 28, 2026, 4:04 PM EDT
Fennec Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 44.64 | 47.54 | 21.25 | 1.54 | - | |
| Revenue Growth (YoY) | -6.09% | 123.69% | 1284.50% | - | - | |
| Cost of Revenue | 3.76 | 3.18 | 1.26 | 0.09 | - | |
| Gross Profit | 40.88 | 44.35 | 19.99 | 1.45 | - | |
| Selling, General & Admin | 46.91 | 41.48 | 32.71 | 20.51 | 12.24 | |
| Research & Development | 0.25 | 0.31 | 0.06 | 3.53 | 4.98 | |
| Operating Expenses | 47.16 | 41.79 | 32.76 | 24.04 | 17.22 | |
| Operating Income | -6.28 | 2.57 | -12.77 | -22.59 | -17.22 | |
| Interest Expense | -2.14 | -4.16 | -3.68 | -1.13 | -0.14 | |
| Interest & Investment Income | 0.79 | 1.68 | 0.44 | 0.2 | 0.05 | |
| Currency Exchange Gain (Loss) | 0.03 | -0.08 | 0.01 | -0.01 | -0.01 | |
| EBT Excluding Unusual Items | -7.61 | 0.01 | -16.01 | -23.53 | -17.32 | |
| Gain (Loss) on Sale of Investments | -0 | -0.08 | -0.04 | -0.18 | -0.03 | |
| Other Unusual Items | -2.02 | - | - | - | - | |
| Pretax Income | -9.64 | -0.07 | -16.05 | -23.71 | -17.35 | |
| Income Tax Expense | 0.11 | 0.37 | - | - | - | |
| Net Income | -9.74 | -0.44 | -16.05 | -23.71 | -17.35 | |
| Net Income to Common | -9.74 | -0.44 | -16.05 | -23.71 | -17.35 | |
| Shares Outstanding (Basic) | 29 | 27 | 27 | 26 | 26 | |
| Shares Outstanding (Diluted) | 29 | 27 | 27 | 26 | 26 | |
| Shares Change (YoY) | 4.70% | 2.71% | 1.14% | 1.03% | 9.71% | |
| EPS (Basic) | -0.34 | -0.02 | -0.60 | -0.90 | -0.67 | |
| EPS (Diluted) | -0.34 | -0.02 | -0.60 | -0.90 | -0.67 | |
| Gross Margin | 91.57% | 93.30% | 94.08% | 94.40% | - | |
| Operating Margin | -14.07% | 5.40% | -60.09% | -1471.60% | - | |
| Profit Margin | -21.82% | -0.92% | -75.50% | -1544.89% | - | |
| EBITDA | -6.18 | 3.6 | - | - | - | |
| EBITDA Margin | -13.84% | 7.57% | - | - | - | |
| D&A For EBITDA | 0.1 | 1.03 | - | - | - | |
| EBIT | -6.28 | 2.57 | -12.77 | -22.59 | -17.22 | |
| EBIT Margin | -14.07% | 5.40% | -60.09% | - | - | |
| Revenue as Reported | 44.64 | 47.54 | 21.25 | - | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.